MA
ANIP icon

MCF Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

MCF Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 823
2022
Q3 		$0 Hold
1
– – ﹤0.01% 813
2022
Q2 		$0 Hold
1
– – ﹤0.01% 765
2022
Q1 		$0 Buy
+1
New +$37 ﹤0.01% 770
2021
Q4 		– Sell
-1
Closed – – 80
2021
Q3 		$0 Buy
+1
New +$31 ﹤0.01% 761

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MCF Advisors's ANIP Position: Q4 2022 in Review

MCF Advisors sold out of ANI Pharmaceuticals (ANIP) in Q4 2022, closing a stake of 1 share.

MCF Advisors first reported a position in ANIP in Q3 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 125 funds tracked by Wall St. Rank hold ANIP as of Q4 2022.

  • MCF Advisors reported no remaining ANI Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • MCF Advisors sold 1 ANI Pharmaceuticals share in Q4 2022.
  • MCF Advisors first reported a position in ANI Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • MCF Advisors's ANI Pharmaceuticals position peaked at $0 in Q3 2022.
  • 125 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2022.

Based on MCF Advisors's 13F filing for Q4 2022, filed 31 Jan 2023.